Details

High-content analysis of 3D chondrogenic pellets derived from primary cells In vitro
ID Voga, Lucija (Author), ID Burnik, Tilen (Author), ID Kandušer, Maša (Author), ID Jeras, Matjaž (Author), ID Zupan, Janja (Author), ID Trojner-Bregar, Andreja (Author)

.pdfPDF - Presentation file, Download (2,85 MB)
MD5: 2C356A7726E287FEDD421DD461A1C90E
URLURL - Source URL, Visit https://www.mdpi.com/2227-9059/14/7/1496 This link opens in a new window

Abstract
Background: Primary cells derived from connective tissues contain mesenchymal stem/stromal cell (MSC)-like progenitors with chondrogenic potential relevant for cartilage repair. However, donor- and tissue-specific variability and the lack of robust, high-content analytical methods limit their translational use. Objectives: This study aimed to develop and optimize a high-content imaging workflow for quantitative evaluation of chondrogenesis in three-dimensional (3D) pellets derived from primary cells. Methods: Primary human cells isolated from cartilage were chondrogenically differentiated in vitro. A systematic optimization of immunofluorescence staining parameters was performed, including staining platform, enzymatic matrix digestion, non-specific site blocking, membrane permeabilization, and nuclear counterstaining. Type II collagen was detected using an Alexa Fluor 488-conjugated antibody, and pellets were analyzed using high-content non-confocal imaging. Fluorescence intensities were adjusted to the pellet area to account for size-dependent effects. Results: Staining directly in imaging plates enabled streamlined high-content analysis. Controlled pepsin-mediated matrix digestion markedly enhanced antibody penetration, while excessive digestion compromised pellet integrity. Extended bovine serum albumin blocking improved type II collagen signal intensity and homogeneity. Triton X-100 permeabilization increased detection sensitivity but occasionally induced structural disruption in weakly organized control pellets. The optimized protocol enabled clear discrimination between chondrogenic pellets and controls, with approximately threefold higher type II collagen signal in chondrogenic samples. Conclusions: This study establishes a high-content imaging-based workflow for quantitative assessment of 3D chondrogenesis from primary cells. The approach provides a rapid, scalable platform with direct relevance for in vitro screening, potency testing, and quality control in cartilage-oriented advanced therapy development.

Language:English
Keywords:3D chondrogenesis, high-content analysis, immunofluorescence, pellets, primary MSCs, type II collagen
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
FKKT - Faculty of Chemistry and Chemical Technology
MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2026
Number of pages:22 str.
Numbering:Vol. 14, iss. 7, art. 1496
PID:20.500.12556/RUL-186567 This link opens in a new window
UDC:602.9
ISSN on article:2227-9059
DOI:10.3390/biomedicines14071496 This link opens in a new window
COBISS.SI-ID:289574403 This link opens in a new window
Publication date in RUL:03.09.2026
Views:138
Downloads:43
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Biomedicines
Shortened title:Biomedicines
Publisher:MDPI
ISSN:2227-9059
COBISS.SI-ID:523006745 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:3D hondrogeneza, analiza visoke vsebnosti, imunofluorescenca, pelete, primarne mezenhimske matične celice, kolagen tipa II, mezenhimske matične celice

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L3-3176
Name:Vloga in možna uporaba imunomodulatornih mezenhimskih matičnih celic v zdravljenjubolezni COVID-19

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0420
Name:Napredna imunološka zdravila in celični pristopi v farmaciji

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:I0-E011
Name:Sofinanciranje izvajanja mednarodnega infrastrukturnega projekta EATRIS

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back